Abstract 4064
Background
The treatment for haematological malignancies is lengthy, complex and intense, leading to potentially debilitating symptoms and reduced health-related quality of life. Patients are living longer due to advancements in early detection and significant improvements in treatment. While treatments for haematological malignancies dramatically increase survivability, many patients suffer from debilitating side effects during and following their treatment. Survivors can suffer long-term effects of both treatment and disease. They may be left with permanent, often devastating, physical impairments leading to an increased risk of other illnesses or a lower quality of life. The presentation is part of a mixed methods study and aims to deepen our understanding of the quality of lives of survivors of adult haematological malignancy. The study will contribute to the under-researched topic related to adult survivors of a haematological malignancy.
Methods
The participants (n = 11) were adults who had completed treatment for a haematological malignancy and were between 1-5 years post-treatment. A qualitative research process of inquiry was used to explore the quality of lives of survivors of haematological malignancy. In-depth face-to-face semi-structured interviews were conducted, based on the content and structure of the interviews envisaged being grounded in the findings of the quantitative phase of the study.
Results
Four themes and several subthemes were generated and reviewed from the qualitative data analysis. The key themes identified in this cohort were:(1) Physical wellbeing (2) Psychological wellbeing (3) Independence and (4) Supportive care needs.
Conclusions
Enhancing these survivors’ physical, psychological wellbeing, an understanding of what independence means to them and addressing supportive care needs can optimise their QoL. Knowledge and understanding of these factors and addressing these needs may provide an insight into implementation measures to enhance the same.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Royal Bournemouth Hospital and Bournemouth University.
Funding
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract